Physician profile
Buffi G Boyd
NPI 1902861917
$6,015.63
in general payments reported to CMS, 2019-2025
37 companies · $385 in 2025
The $385 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $350 · 2020: $3,274 · 2021: $610 · 2022: $424 · 2023: $405 · 2024: $568 · 2025: $385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,358.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,357.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,183.73 | 2020 | |
| Abbvie INC. | $717.19 | 2020-2025 | Botox, Lupron Depot |
| Pfizer INC. | $239.66 | 2019-2024 | |
| Astellas Pharma US INC | $235.84 | 2019-2025 | Xtandi, Myrbetriq |
| Sumitomo Pharma America, INC. | $227.97 | 2023-2025 | Orgovyx, Gemtesa |
| Medtronic, INC. | $174.75 | 2023-2025 | Interstim |
| Merck Sharp & Dohme LLC | $158.51 | 2021-2024 | Keytruda, Lynparza, Welireg |
| Allergan, INC. | $120.05 | 2019-2022 | |
| Myovant Sciences INC. | $114.11 | 2021 | |
| Endo Pharmaceuticals INC. | $109.74 | 2020-2024 | Xiaflex |
| Coloplast Corp | $100.04 | 2019-2025 | Porges Coloplast |
| Bayer Healthcare Pharmaceuticals INC. | $72.04 | 2019-2023 | |
| Boston Scientific Corporation | $65.03 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $48.63 | 2021-2022 | |
| Amgen INC. | $45.99 | 2019-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $39.72 | 2019 | |
| Urogen Pharma, INC. | $35.89 | 2021-2023 | Jelmyto |
| Novartis Pharmaceuticals Corporation | $35.48 | 2022-2025 | |
| Davol INC. | $31.41 | 2024 | Arista Ah Flexitip |
| Rochester Medical Corporation | $26.16 | 2022 | |
| Verity Pharmaceuticals INC. | $24.83 | 2025 | Tlando |
| Ferring Pharmaceuticals INC. | $21.77 | 2019 | |
| Calyxo, INC. | $21.32 | 2025 | Cvac Aspiration System |
| Blue Earth Diagnostics | $20.42 | 2023 | |
| Olympus America INC. | $19.64 | 2025 | Itind System |
| Therapeuticsmd, INC. | $19.45 | 2019 | |
| Dendreon Pharmaceuticals LLC | $18.87 | 2021 | |
| 180 Medical, INC. | $17.47 | 2021 | |
| Urovant Sciences INC | $14.52 | 2022 | |
| Neotract INC. | $13.22 | 2019 | |
| Innovation Technologies INC | $13.19 | 2024 | Irrisept |
| Medtronic USA, INC. | $12.85 | 2019 | |
| Foundation Medicine, INC. | $12.34 | 2022 | |
| Travere Therapeutics, INC. | $3.80 | 2019-2022 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Buffi Boyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.